This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact The Epoch Times Reprints.
The revision is a step toward finalizing the transition from Paxlovid’s emergency use authorization to its new drug application label, initiated in late 2023.
Researchers believe they’ve identified the mechanisms that allow the SARS-CoV-2 virus to be so effective at making us sick.
Researchers found little difference in outcomes between Paxlovid users and nonusers. They also found 1 in 5 users experienced rebound symptoms.
Only 2018 featured a higher number of drug approvals.
Many Paxlovid recipients have suffered from renewed symptoms.
Out of the 31 long COVID conditions, Paxlovid was found to minimize the incidence of only one.
Pfizer projects Paxlovid sales to fall by 58 percent this year compared to 2022.
Researchers said that both oral antiviral drugs can be used to treat nonhospitalized patients at high risk of progressing to severe COVID-19.
